Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 12/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.51 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9792723 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1KDM4E | |
| SCHEMBL13163119 | 1.00 | OPRM1 (0.51) | OPRM1OPRD1OPRK1OPRL1KDM4E | |
| SCHEMBL14257980 | 0.89 | KDM4E (0.56) | OPRM1OPRD1OPRK1OPRL1KDM4E | |
| SCHEMBL13291353 | 0.89 | KDM4E (0.56) | OPRM1OPRD1OPRK1OPRL1KDM4E | |
| SCHEMBL13955139 | 0.79 | OPRD1 (0.50) | OPRM1OPRD1OPRK1OPRL1KDM4E | |
| SCHEMBL4153281 | 0.78 | MEN1 (0.53) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL4153276 | 0.78 | MEN1 (0.53) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL5368864 | 0.76 | OPRM1 (0.47) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL6025516 | 0.76 | OPRM1 (0.48) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL23764718 | 0.75 | KDM4E (0.48) | OPRM1OPRD1OPRK1OPRL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115361999-B | 2- [ 2-Methylazetidin-1-yl ] -4-phenyl-6- (trifluoromethyl) -pyrimidine compounds | 伊莱利利公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-112601525-B | 2, 6-diaminopyridine compounds | 伊莱利利公司 | 2023-11-10 | — | — | CN | disclosed |
| EP-3983404-B1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHBITORS | LILLY CO ELI (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230167087-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167087-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230135552-A1 | Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same | INORBIT THERAPEUTICS AB (SE) | 2023-05-04 | — | — | US | disclosed |
| US-20230135552-A1 | Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same | INORBIT THERAPEUTICS AB (SE) | 2023-05-04 | — | — | US | disclosed |
| US-20230135552-A1 | Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same | INORBIT THERAPEUTICS AB (SE) | 2023-05-04 | — | — | US | disclosed |
| EP-4106762-A1 | COMPOUNDS USEFUL IN INHIBITING KETOHEXOKINASE AND METHODS OF MAKING AND USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2022-12-28 | — | — | EP | disclosed |
| CN-115361999-A | 2- [ 2-methylazetidin-1-yl ] -4-phenyl-6- (trifluoromethyl) -pyrimidine compounds | 伊莱利利公司 | 2022-11-18 | — | — | CN | disclosed |
| CN-115315259-A | Compounds useful for inhibition of ketohexokinase and methods of making and using the same | 因奥必治疗有限公司 | 2022-11-08 | — | — | CN | disclosed |
| WO-2022135390-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | 四川海思科制药有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20220017496-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY | 2022-01-20 | — | — | US | disclosed |
| US-11124500-B2 | Disubstituted pyrazole compounds | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2021161023-A1 | COMPOUNDS USEFUL IN INHIBITING KETOHEXOKINASE AND METHODS OF MAKING AND USING THE SAME | INORBIT THERAPEUTICS AB (SE) | 2021-08-19 | — | — | WO | disclosed |
| EP-3846809-A1 | 2,6-DIAMINO PYRIDINE COMPOUNDS | Eli Lilly and Company (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2020257171-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS AS KETOHEXOKINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392118-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | ELI LILLY AND COMPANY | 2020-12-17 | — | — | US | disclosed |
| US-10781212-B2 | 2,6-diamino pyridine compounds | ELI LILLY AND COMPANY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20200071331-A1 | 2,6-DIAMINO PYRIDINE COMPOUNDS | LILLY CO ELI (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124500-B2 | Disubstituted pyrazole compounds | SLC5A2, SLC5A1, GOT2 | OPRM1 4395/4885OPRD1 3957/4885OPRK1 2765/4885 |
| US-20200392118-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | SLC5A2, SLC5A1, GOT2 | OPRM1 4395/4885OPRD1 3957/4885OPRK1 2765/4885 |
| US-20220017496-A1 | DISUBSTITUTED PYRAZOLE COMPOUNDS | SLC5A2, SLC5A1, GOT2 | OPRM1 4250/4885OPRD1 3755/4885OPRK1 2610/4885 |
| US-20230167087-A1 | 2-[2-METHYLAZETIDIN-1-YL]-4-PHENYL-6-(TRIFLUOROMETHYL)-PYRIMIDINE COMPOUNDS | SLC5A2, GOT2, FABP1 | OPRM1 3186/4885OPRD1 3289/4885OPRK1 2678/4885 |
| US-20200071331-A1 | 2,6-DIAMINO PYRIDINE COMPOUNDS | SLC5A2, GOT2, SLC5A1 | OPRM1 3975/4885OPRD1 4252/4885OPRK1 3086/4885 |
| US-10781212-B2 | 2,6-diamino pyridine compounds | SLC5A2, GOT2, SLC5A1 | OPRM1 3975/4885OPRD1 4252/4885OPRK1 3086/4885 |
| US-20230135552-A1 | Compounds Useful In Inhibiting Ketohexokinase And Methods Of Making And Using The Same | KHK, GCK, HK1 | OPRM1 4368/4885OPRD1 4553/4885OPRK1 777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.